metformin has been researched along with regorafenib in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
Guo, X; Yang, L; Yang, Q | 1 |
2 other study(ies) available for metformin and regorafenib
Article | Year |
---|---|
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
Metformin Enhances the Effect of Regorafenib and Inhibits Recurrence and Metastasis of Hepatic Carcinoma After Liver Resection via Regulating Expression of Hypoxia Inducible Factors 2α (HIF-2α) and 30 kDa HIV Tat-Interacting Protein (TIP30).
Topics: Acetyltransferases; Animals; Apoptosis; Basic Helix-Loop-Helix Transcription Factors; Carcinoma, Hepatocellular; Cell Hypoxia; Cell Line, Tumor; Cell Proliferation; Cell Survival; Epithelial-Mesenchymal Transition; Gene Expression Regulation, Neoplastic; Hepatectomy; Humans; Hypoxia; Liver; Liver Neoplasms; Metformin; Mice; Mice, Inbred BALB C; Neoplasm Metastasis; Neoplasm Recurrence, Local; Phenylurea Compounds; Pyridines; Transcription Factors | 2018 |